1
Country: USA | Funding: $3.5B
We are developing tools and platforms to enable more continuous health data collection for timely decision-making and effective interventions. We are running longitudinal studies to better understand ways to predict and prevent disease onset and progression. And, we are undertaking significant joint efforts with partners to radically transform the way healthcare is delivered.
We are developing tools and platforms to enable more continuous health data collection for timely decision-making and effective interventions. We are running longitudinal studies to better understand ways to predict and prevent disease onset and progression. And, we are undertaking significant joint efforts with partners to radically transform the way healthcare is delivered.
2
Country: USA | Funding: $2.4B
Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.
Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.
3
Country: Netherlands | Funding: $1.2B
Founded is a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases
Founded is a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases
4
Country: USA | Funding: $733.3M
Windtree Therapeutics develops cardiovascular drugs. Its flagship drug Istaroxime is a first-in-class, dual-mode therapy designed to improve cardiac function by increasing both systolic contractility and diastolic relaxation through SERCA2a activation and Na+/K+ ATPase inhibition. The company's heart failure portfolio also includes sarcoendoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) activators, which activate SERCA2a. These candidates will be developed as potential oral treatments for chronic heart failure.
Windtree Therapeutics develops cardiovascular drugs. Its flagship drug Istaroxime is a first-in-class, dual-mode therapy designed to improve cardiac function by increasing both systolic contractility and diastolic relaxation through SERCA2a activation and Na+/K+ ATPase inhibition. The company's heart failure portfolio also includes sarcoendoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) activators, which activate SERCA2a. These candidates will be developed as potential oral treatments for chronic heart failure.
5
Country: USA | Funding: $603.2M
Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.
Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.
6
Country: USA | Funding: $554M
Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures.
Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures.
7
Country: USA | Funding: $419.3M
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
8
Country: USA | Funding: $390.6M
CVRx developed an implantable technology, called Barostim neo, for the treatment of high blood pressure and heart failure.
CVRx developed an implantable technology, called Barostim neo, for the treatment of high blood pressure and heart failure.
9
Country: USA | Funding: $386.5M
Cleerly is a digital healthcare company that provides diagnostic solutions for people with heart disease.
Cleerly is a digital healthcare company that provides diagnostic solutions for people with heart disease.
10
Country: USA | Funding: $368.4M
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
11
Country: Canada | Funding: $360.9M
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
12
Country: USA | Funding: $337.8M
Orchestra BioMed is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. The main focus is on developing new therapies for cardiovascular diseases
Orchestra BioMed is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. The main focus is on developing new therapies for cardiovascular diseases
13
Country: USA | Funding: $337.3M
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
14
Country: USA | Funding: $290M
Rivus Pharmaceuticals is dedicated to improving metabolic health by developing controlled metabolic accelerators (CMAs) that treat metabolic disorders, including the tricky nonalcoholic steatohepatitis (NASH), cardio-metabolic diseases and obesity, via weight loss.
Rivus Pharmaceuticals is dedicated to improving metabolic health by developing controlled metabolic accelerators (CMAs) that treat metabolic disorders, including the tricky nonalcoholic steatohepatitis (NASH), cardio-metabolic diseases and obesity, via weight loss.
15
Country: France | Funding: €258.1M
The mission of every team member at Carmat is to contribute to the development of innovative artificial organs – the artificial heart today, tomorrow other vital organs – to treat millions of patients affected by advanced disease of these organs and to restore their normal life.
The mission of every team member at Carmat is to contribute to the development of innovative artificial organs – the artificial heart today, tomorrow other vital organs – to treat millions of patients affected by advanced disease of these organs and to restore their normal life.
16
Country: Canada | Funding: $225M
BlueRock Therapeutics is pioneering cell therapies that replace dead, damaged, or dysfunctional cells to restore critical natural functions in the body. The company is initially targeting severe brain and heart conditions, two areas of critical unmet medical need with blockbuster potential.
BlueRock Therapeutics is pioneering cell therapies that replace dead, damaged, or dysfunctional cells to restore critical natural functions in the body. The company is initially targeting severe brain and heart conditions, two areas of critical unmet medical need with blockbuster potential.
17
Country: Israel | Funding: $179M
Magenta Medical has developed a temporary venous catheter-based therapy for hospital-admitted patients with Acute Decompensated Heart Failure (ADHF).
Magenta Medical has developed a temporary venous catheter-based therapy for hospital-admitted patients with Acute Decompensated Heart Failure (ADHF).
18
Country: USA | Funding: $173.2M
Eko creates FDA approved software, AI, and heart sound and EKG sensors for heart disease monitoring.
Eko creates FDA approved software, AI, and heart sound and EKG sensors for heart disease monitoring.
19
Country: USA | Funding: $166.2M
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
20
Country: USA | Funding: $154.3M
AliveCor is a leading FDA-cleared mobile heart solution that helps save lives, save money, and bring healthcare into the 21st century.
AliveCor is a leading FDA-cleared mobile heart solution that helps save lives, save money, and bring healthcare into the 21st century.
